Association between baseline blood pressure and the incidence of lenvatinib-induced hypertension in patients with thyroid cancer.
Yuma ShibutaniKazuko TajiriShinya SuzukiTomohiro EnokidaAtsunobu SagaraSusumu OkanoTakao FujisawaFumiaki SatoTetsuro YumotoMotohiko SanoToshikatsu KawasakiMakoto TaharaPublished in: Cancer medicine (2023)
Lenvatinib-induced hypertension appears the day after administration, and higher baseline blood pressure is a significant risk factor for developing hypertension grade ≥3. In cases of increased blood pressure with lenvatinib, early initiation of antihypertensives may prevent treatment interruption due to hypertension and maintain the therapeutic intensity of lenvatinib.